JP2023524874A - ナノ粒子の組成物 - Google Patents

ナノ粒子の組成物 Download PDF

Info

Publication number
JP2023524874A
JP2023524874A JP2022568554A JP2022568554A JP2023524874A JP 2023524874 A JP2023524874 A JP 2023524874A JP 2022568554 A JP2022568554 A JP 2022568554A JP 2022568554 A JP2022568554 A JP 2022568554A JP 2023524874 A JP2023524874 A JP 2023524874A
Authority
JP
Japan
Prior art keywords
nanoparticles
composition
group
poly
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022568554A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524874A5 (enExample
Inventor
アルミン キューベルベック，
Original Assignee
ライフ サイエンス インクバトーア ベトリープス ゲーエムベーハー ウント コンパニー カーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライフ サイエンス インクバトーア ベトリープス ゲーエムベーハー ウント コンパニー カーゲー filed Critical ライフ サイエンス インクバトーア ベトリープス ゲーエムベーハー ウント コンパニー カーゲー
Publication of JP2023524874A publication Critical patent/JP2023524874A/ja
Publication of JP2023524874A5 publication Critical patent/JP2023524874A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022568554A 2020-05-12 2021-05-12 ナノ粒子の組成物 Pending JP2023524874A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20174156.8A EP3909612A1 (en) 2020-05-12 2020-05-12 Composition of nanoparticles
EP20174156.8 2020-05-12
PCT/EP2021/062751 WO2021229015A1 (en) 2020-05-12 2021-05-12 Composition of nanoparticles

Publications (2)

Publication Number Publication Date
JP2023524874A true JP2023524874A (ja) 2023-06-13
JP2023524874A5 JP2023524874A5 (enExample) 2024-05-22

Family

ID=70682623

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022568554A Pending JP2023524874A (ja) 2020-05-12 2021-05-12 ナノ粒子の組成物
JP2022568723A Pending JP2023529065A (ja) 2020-05-12 2021-05-12 Ｈｐｖ由来の免疫原性フラグメントのためのの担体としてのナノ粒子の組成物
JP2022568724A Pending JP2023529066A (ja) 2020-05-12 2021-05-12 アジュバント／抗原の担体系としてのナノ粒子

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022568723A Pending JP2023529065A (ja) 2020-05-12 2021-05-12 Ｈｐｖ由来の免疫原性フラグメントのためのの担体としてのナノ粒子の組成物
JP2022568724A Pending JP2023529066A (ja) 2020-05-12 2021-05-12 アジュバント／抗原の担体系としてのナノ粒子

Country Status (4)

Country Link
US (4) US20230272014A1 (enExample)
EP (6) EP3909612A1 (enExample)
JP (3) JP2023524874A (enExample)
WO (3) WO2021229020A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3909612A1 (en) * 2020-05-12 2021-11-17 Life Science Inkubator Betriebs GmbH & Co. KG Composition of nanoparticles
CN113274492B (zh) * 2021-05-21 2022-06-17 大连理工大学 一种基于羟基氧化铝纳米羧基改性的复合疫苗佐剂的制备方法
US20240042070A1 (en) * 2022-06-28 2024-02-08 Transcode Therapeutics, Inc. Nanoparticles and template directed rig-i agonist precursor compositions and uses thereof for cancer therapy
EP4673166A1 (en) * 2023-03-02 2026-01-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Therapeutic hpv vaccines based on validated target epitopes
WO2024180234A1 (en) * 2023-03-02 2024-09-06 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Validated hpv16-derived stimulation peptides
WO2024180233A1 (en) * 2023-03-02 2024-09-06 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts A therapeutic hpv vaccine based on validated target epitopes

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056288A1 (de) * 1999-03-19 2000-09-28 Institut Für Neue Materialien Gem. Gmbh Nanoskalige teilchen, komplexe mit polynukleotiden und deren verwendung
WO2006017476A2 (en) * 2004-08-02 2006-02-16 The Research Foundation Of State University Of New York Amino functionalized ormosil nanoparticles as delivery vehicles
JP2009274923A (ja) * 2008-05-15 2009-11-26 Furukawa Electric Co Ltd:The 粒子表面にアミノ基を有するシリカ粒子の製造方法、粒子表面にアミノ基を有するシリカ粒子、及びそれを用いた複合粒子
JP2017529384A (ja) * 2014-07-22 2017-10-05 レモネックス インコーポレイテッドLemonex Inc. 生理活性物質又はタンパク質伝達用組成物及びその用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3616133A1 (de) 1985-09-25 1987-11-19 Merck Patent Gmbh Kugelfoermige sio(pfeil abwaerts)2(pfeil abwaerts)-partikel
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
DE69425356T2 (de) 1993-09-22 2002-04-18 Hoechst Ag Pro-Prodrugs, ihre Herstellung und Anwendung
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
NZ517928A (en) 1999-09-27 2004-09-24 Coley Pharm Gmbh Methods related to immunostimulatory nucleic acid-induced interferon
IL153474A0 (en) * 2000-06-26 2003-07-06 Stressgen Biotechnologies Corp Human papilloma virus treatment
DE102004011110A1 (de) 2004-03-08 2005-09-22 Merck Patent Gmbh Verfahren zur Herstellung monodisperser SiO2-Partikel
WO2006037979A2 (en) 2004-10-01 2006-04-13 Midatech Limited Nanoparticles comprising antigens and adjuvants and immunogenic structure
JP4981681B2 (ja) 2004-12-09 2012-07-25 アルナイラム ファーマシューティカルズ， インコーポレイテッド 哺乳類における免疫応答誘導組成物および方法、ならびに短鎖干渉ｒｎａなどのオリゴヌクレオチド剤に対する免疫応答の回避方法
WO2006070376A1 (en) * 2004-12-30 2006-07-06 Hadasit Medical Research Services & Development Ltd. Antimicrobial nanoparticulate additives forming non-leachable sustained antimicrobial polymeric compositions
EP1764107A1 (en) 2005-09-14 2007-03-21 Gunther Hartmann Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides
AU2006290567A1 (en) 2005-09-14 2007-03-22 Ucb Pharma S.A Comb polymers
SI2056845T1 (en) 2006-08-08 2018-02-28 Rheinische Friedrich-Wilhelms-Universitaet Bonn STRUCTURE AND USE 5 'PHOSPHATE OF OLIGONUCLEOTES
FR2908305B1 (fr) 2006-11-10 2009-02-27 Oreal Procede de deformation permanente des fibres keratiniques comprenant une etape d'application d'une composition de rincage intermediaire comprenant un sel de cation metallique monovalent ou un sel d'ammonium et un acide organique
EP2297323A1 (en) 2008-05-21 2011-03-23 Hartmann, Gunther 5' triphosphate oligonucleotide with blunt end and uses thereof
EP4015636B1 (en) 2008-05-21 2024-11-20 Rheinische Friedrich-Wilhelms-Universität Bonn 5' triphosphate oligonucleotide with blunt end and uses thereof
DE102008033175A1 (de) 2008-07-15 2010-01-21 Merck Patent Gmbh Siliciumdioxid-Nanopartikel und deren Verwendung zur Vakzinierung
AU2010225129A1 (en) 2009-03-17 2010-09-23 Gunther Hartmann TLR7 ligand and uses thereof
ES2366841B1 (es) * 2010-04-06 2013-01-24 Consejo Superior De Investigaciones Cientificas (Csic) (45%) Nanoparticulas de silice para difusion intracelular de agentes bioactivos poco solubles
AU2011263546B2 (en) 2010-06-10 2015-01-22 Midatech Limited Peptide-carrying nanoparticles
DE102011018499A1 (de) * 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
AU2012306243B2 (en) 2011-09-07 2016-10-20 Midatech Limited Nanoparticle-peptide compositions
MX2014002764A (es) 2011-09-07 2014-12-04 Midatech Ltd Vacunas en nanoparticulas para tumor.
EP2883550A1 (en) 2013-12-12 2015-06-17 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Novel promiscuous HPV16-derived T helper epitopes for immunotherapy
EP3134124B1 (en) 2014-04-25 2019-02-20 Pierre Fabre Medicament Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
WO2016054225A1 (en) * 2014-09-30 2016-04-07 Stc.Unm Plasmid delivery in the treatment of cancer and other disease states
EP3370741B1 (en) * 2015-11-04 2025-10-08 The Trustees of the University of Pennsylvania Methods and compositions for gene editing in hematopoietic stem cells
KR102317281B1 (ko) * 2015-11-17 2021-10-25 하이라이트 테라퓨틱스 에스.엘. 이본쇄 폴리리보뉴클레오타이드 및 폴리알킬렌이민의 복합체를 포함하는 입자를 포함하는 신규 약제학적 조성물
WO2017223085A2 (en) * 2016-06-20 2017-12-28 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
WO2018085751A1 (en) 2016-11-07 2018-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of agonist epitopes of the human papillomavirus
US20200375912A1 (en) * 2017-08-03 2020-12-03 Rita Elena Serda Liposomal coated nanoparticles for immunotherapy applications
GB201718817D0 (en) * 2017-11-14 2017-12-27 N4 Pharma Uk Ltd Particulate material production process
US20210196838A1 (en) * 2018-08-24 2021-07-01 Mirexus Biotechnologies Inc. Compounds and compositions for potentiation of tlr agonists
EP3909612A1 (en) * 2020-05-12 2021-11-17 Life Science Inkubator Betriebs GmbH & Co. KG Composition of nanoparticles

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056288A1 (de) * 1999-03-19 2000-09-28 Institut Für Neue Materialien Gem. Gmbh Nanoskalige teilchen, komplexe mit polynukleotiden und deren verwendung
WO2006017476A2 (en) * 2004-08-02 2006-02-16 The Research Foundation Of State University Of New York Amino functionalized ormosil nanoparticles as delivery vehicles
JP2009274923A (ja) * 2008-05-15 2009-11-26 Furukawa Electric Co Ltd:The 粒子表面にアミノ基を有するシリカ粒子の製造方法、粒子表面にアミノ基を有するシリカ粒子、及びそれを用いた複合粒子
JP2017529384A (ja) * 2014-07-22 2017-10-05 レモネックス インコーポレイテッドLemonex Inc. 生理活性物質又はタンパク質伝達用組成物及びその用途

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ACTA BIOMATERIALIA, vol. 40, JPN6025020830, 2016, pages 273 - 281, ISSN: 0005750900 *
INDONES. J. CHEM., vol. 17 (2), JPN6025020831, 2017, pages 256 - 263, ISSN: 0005750901 *
INTERNATIONAL JOURNAL OF NANOMEDICINE, vol. 9 (Suppl 2), JPN6025020832, 2014, pages 29 - 40, ISSN: 0005750903 *
INTERNATIONAL JOURNAL OF NANOMEDICINE, vol. 9 (Suppl 2), JPN6025050399, 2014, pages 183 - 193, ISSN: 0005750899 *
INTERNATIONAL JOURNAL OF NANOMEDICINE, vol. 9 (Suppl 2), JPN6025050400, 2014, pages 3 - 10, ISSN: 0005750898 *
INTERNATIONAL JOURNAL OF NANOMEDICINE, vol. 9(Suppl 2), JPN6025020834, 2014, pages 207 - 215, ISSN: 0005750902 *
LANGMUIR, vol. 28, JPN6025020833, 2012, pages 7598 - 7613, ISSN: 0005750904 *

Also Published As

Publication number Publication date
EP3909612A1 (en) 2021-11-17
US20240197909A1 (en) 2024-06-20
US20260000754A1 (en) 2026-01-01
EP4149561A1 (en) 2023-03-22
WO2021229020A1 (en) 2021-11-18
EP3909614A1 (en) 2021-11-17
EP3909613A1 (en) 2021-11-17
US20230181727A1 (en) 2023-06-15
WO2021229015A1 (en) 2021-11-18
JP2023529066A (ja) 2023-07-07
WO2021229014A1 (en) 2021-11-18
EP4149560A1 (en) 2023-03-22
EP4149562A1 (en) 2023-03-22
US20230272014A1 (en) 2023-08-31
JP2023529065A (ja) 2023-07-07

Similar Documents

Publication Publication Date Title
US20260000754A1 (en) Nanoparticles as carrier-system for adjuvants/antigens
Yoshizaki et al. pH-sensitive polymer-modified liposome-based immunity-inducing system: effects of inclusion of cationic lipid and CpG-DNA
US20230381306A1 (en) Structure-Function Relationships in the Development of Immunotherapeutic Agents
JP5715051B2 (ja) リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物
TWI558412B (zh) 包含陽離子性脂質之組合物及其用途
JP4535211B2 (ja) コクリエート送達ビヒクル
Beaudette et al. In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines
US10300145B2 (en) Synthetic nanoparticles for delivery of immunomodulatory compounds
CN105792843B (zh) 佐剂组合物及包含其的疫苗组合物、以及它们的制造方法
Liu et al. A cell-penetrating peptide-assisted nanovaccine promotes antigen cross-presentation and anti-tumor immune response
CN108324938B (zh) 一种颗粒型佐剂及其制备方法和应用
US20230149535A1 (en) Vaccines for coronavirus and methods of using the same
Liu et al. A simple self-adjuvanting biomimetic nanovaccine self-assembled with the conjugate of phospholipids and nucleotides can induce a strong cancer immunotherapeutic effect
JPWO2017007027A1 (ja) 免疫刺激オリゴヌクレオチド複合体
CN114939159A (zh) 一种载病毒抗原和佐剂的多级靶向载体的构建及应用
US20240398918A1 (en) Design of immunostimulatory protein-core spherical nucleic acids
Li et al. Pattern recognition receptors and their nano-adjuvants for cancer immunotherapy
CN110022894A (zh) 用于癌症疗法的免疫原性化合物
US12239703B2 (en) Composite-type nano-vaccine particle
Schlich et al. Boosting antigen-specific T cell activation with lipid-stabilized protein nanoaggregates
Yang et al. Combination application of Pickering emulsion and BLS protein nanoparticles enhances vaccine efficacy
Orosco et al. Next-generation subunit vaccine delivery systems: Design, applications, and prospects
KR102529194B1 (ko) 바이러스 감염증 예방 또는 치료용 백신
Ohta Cholesteryl Pullulan Nanoparticles-Encapsulated TNF-a: An Effective Mucosal Vaccine Adjuvant Against
WO2026034613A1 (ja) ｍＲＮＡワクチンアジュバント

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240513

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260304